Historical FDA Approval for Carvykti
Friday, the FDA gave the green light to Johnson & Johnson‘s Carvykti for relapsed or refractory multiple myeloma patients who are refractory to lenalidomide.
Redefining Multiple Myeloma Treatment
Carvykti becomes the first BCMA-targeted therapy approved for multiple myeloma treatment at the first relapse, setting a new standard in the field.
Manufacturing Milestones
As demand for Carvykti grows, Johnson & Johnson vows to double manufacturing capacity in anticipation of heightened patient needs.
Strategic Collaborations for Success
Through partnerships with industry giants like Novartis AG, Johnson & Johnson is poised to expand manufacturing efforts to meet the rising demand for Carvykti.
Market Dynamics and Future Outlook
Despite its current dominance in the multiple myeloma treatment market, Carvykti faces potential challenges from upcoming BCMA-targeted products.
Price Action Update
As of Monday, JNJ shares are down 0.15% at $152.17, while LEGN shares are down 1.19% at $54.28.
Photo via Shutterstock
